Journal of hepatologyHumansCarcinomaHepatocellularPhenylurea CompoundsLiver Neoplasms
Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab.
Hyung-Don Kim, Sun Jin Sym, Hong Jae Chon, Moonho Kim, Jung Hun Kang, Baek-Yeol Ryoo, Choong-Kun Lee, Joohyun Hong, Hyewon Ryu, Woo Kyun Bae, Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae-Yong Kim, Changhoon Yoo
Published: 202610.1016/j.jhep.2025.08.020
Abstract
BACKGROUND & AIMS: Atezolizumab plus bevacizumab (atezo-bev) is the global standard first-line therapy for unresectable hepatocellular carcinoma (uHCC). However, most patients eventually experience disease progression and optimal second-line strategi…
Preview only. Read the full abstract at the source